---
title: "Mankind Pharma Ltd (MANKIND) — Share Price, Financials & Analysis"
symbol: "MANKIND"
company: "Mankind Pharma Ltd"
canonical: "https://tapetide.com/stocks/MANKIND"
isin: "INE634S01028"
nse_symbol: "MANKIND"
bse_code: "543904"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 92222
generated_at: "2026-09-13T18:59:13.257Z"
---

# Mankind Pharma Ltd (MANKIND)

Canonical page: https://tapetide.com/stocks/MANKIND

## Company

- **NSE Symbol:** MANKIND
- **BSE Code:** 543904
- **ISIN:** INE634S01028
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2023-05-09
- **Face Value:** ₹1
- **F&O Eligible:** Yes
- **Website:** mankindpharma.com

## About

Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.[1]

## Latest Price

- **Price:** ₹2280
- **Change:** +41.6 (+1.86%)
- **Open:** ₹2237.2
- **Day High:** ₹2280
- **Day Low:** ₹2222
- **Previous Close:** ₹2238.4
- **Volume:** 530698
- **As Of:** 2026-09-11T10:28:42+00:00

## Key Fundamentals

Observed at 2026-09-11T04:51:42.683091Z.

- **Market Cap:** ₹92222 Cr
- **Classification:** Midcap
- **P/E (reported):** 44.9
- **P/E (TTM):** 46.09
- **EPS (TTM):** ₹49.47
- **EPS (reported):** ₹48.99
- **Book Value:** ₹394.64
- **Price to Book:** 5.69
- **Dividend Yield:** 0.04%
- **ROE:** 11.7%
- **ROCE:** 13.78%
- **Debt to Equity:** 0.39
- **Revenue (yearly):** ₹14636.4 Cr
- **Net Income:** ₹1938.1 Cr
- **EBITDA:** ₹3976.2 Cr
- **52-Week High:** ₹2674
- **52-Week Low:** ₹1909.7
- **RSI (14):** 30.12

## Tapetide Score

- **Score:** 45 / 100
- **Score date:** 2026-09-04
- **Archetype:** Out of Favour
- **What it means:** Financially sound, yet the market is not rewarding it. Cases like this usually need a specific reason the pessimism is misplaced, and patience for that reason to play out.
- **Pillar profile:** Quality: Good · Valuation: Fair · Momentum: Falling
- **Percentile:** 28.3 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 30.71 | 9% |
| growth | 36.71 | 9% |
| momentum | 22.1 | 12% |
| ownership | 33.34 | 24% |
| quality | 71.55 | 22% |
| valuation | 52.72 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has reduced debt.

### Weaknesses

- Promoter holding has decreased over last 3 years: -3.87%

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 29.33% | 45.01% | 239.35% |
| ebitda margin growth | 7.92% | -2.58% | 2.49% | -0.8% |
| net income growth | 2.63% | -3.41% | 17% | 11% |
| revenue growth | 14.59% | 14.85% | 18% | 18% |
| roce | 9.8% | 3.38% | -44.19% | 20.96% |
| roe | 2.62% | -15.03% | 15.25% | -49.13% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 2708 | 2607 | 2422 | 2868 | 3061 | 3199 | 3079 | 3570 | 3697 | 3567 | 3443 | 4031 |
| Expenses | 2025 | 2000 | 1836 | 2196 | 2214 | 2383 | 2396 | 2724 | 2776 | 2648 | 2513 | 2974 |
| Operating Profit | 683 | 606 | 586 | 672 | 847 | 816 | 683 | 847 | 921 | 919 | 930 | 1056 |
| OPM % | 25 | 23 | 24 | 23 | 28 | 26 | 22 | 24 | 25 | 26 | 27 | 26 |
| Other Income | 63 | 75 | 94 | 108 | 109 | 87 | 249 | 83 | 94 | -31 | 94 | 49 |
| Interest | 9 | 9 | 9 | 11 | 7 | 221 | 191 | 171 | 170 | 157 | 142 | 110 |
| Depreciation | 96 | 110 | 100 | 103 | 100 | 187 | 231 | 219 | 222 | 223 | 223 | 226 |
| Profit before tax | 641 | 562 | 572 | 666 | 849 | 495 | 511 | 540 | 624 | 509 | 659 | 769 |
| Tax % | 20 | 18 | 17 | 18 | 22 | 22 | 17 | 18 | 17 | 19 | 15 | 25 |
| Net Profit | 511 | 460 | 477 | 543 | 659 | 385 | 425 | 445 | 520 | 414 | 559 | 574 |
| EPS in Rs | 12.51 | 11.33 | 11.76 | 13.39 | 16.31 | 9.22 | 10.2 | 10.62 | 12.39 | 9.9 | 13.43 | 13.75 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 3334 | 5865 | 6214 | 7782 | 8749 | 10260 | 12207 | 14278 | 14738 |
| Expenses | 2748 | 4427 | 4565 | 5791 | 6848 | 7743 | 9182 | 10653 | 10911 |
| Operating Profit | 586 | 1438 | 1649 | 1991 | 1902 | 2517 | 3026 | 3625 | 3827 |
| OPM % | 18 | 25 | 27 | 26 | 22 | 25 | 25 | 25 | 26 |
| Other Income | 76 | 122 | 183 | 210 | 141 | 295 | 548 | 238 | 207 |
| Interest | 2 | 23 | 21 | 60 | 46 | 34 | 432 | 644 | 579 |
| Depreciation | 39 | 99 | 119 | 167 | 326 | 378 | 621 | 886 | 893 |
| Profit before tax | 621 | 1438 | 1692 | 1975 | 1671 | 2399 | 2521 | 2333 | 2562 |
| Tax % | 29 | 27 | 24 | 26 | 22 | 19 | 20 | 17 | — |
| Net Profit | 445 | 1056 | 1293 | 1453 | 1310 | 1942 | 2011 | 1938 | 2068 |
| EPS in Rs | 219.33 | 25.72 | 31.59 | 35.78 | 32 | 47.75 | 48.26 | 46.34 | 49.47 |
| Dividend Payout % | 0 | 0 | 24 | 0 | 0 | 0 | 0 | 2 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 20 | 40 | 40 | 40 | 40 | 40 | 41 | 41 |
| Reserves | 2035 | 3445 | 4682 | 6115 | 7395 | 9323 | 14291 | 16259 |
| Borrowings | 0 | 131 | 241 | 873 | 170 | 207 | 8511 | 6312 |
| Other Liabilities | 968 | 1449 | 1397 | 2080 | 2080 | 2313 | 4808 | 5143 |
| Total Liabilities | 3022 | 5065 | 6360 | 9108 | 9686 | 11883 | 27652 | 27755 |
| Fixed Assets | 316 | 1600 | 1664 | 3588 | 4251 | 4545 | 19005 | 18620 |
| CWIP | 47 | 317 | 372 | 701 | 550 | 282 | 826 | 1128 |
| Investments | 959 | 829 | 1512 | 1109 | 1346 | 2568 | 2042 | 1985 |
| Other Assets | 1700 | 2319 | 2811 | 3709 | 3538 | 4488 | 5780 | 6022 |
| Total Assets | 3022 | 5065 | 6360 | 9108 | 9686 | 11883 | 27652 | 27755 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | — | 1070 | 1137 | 920 | 1813 | 2152 | 2413 | 3121 |
| Cash from Investing Activity | — | -436 | -1222 | -1369 | -1052 | -2081 | -12624 | -181 |
| Cash from Financing Activity | — | -531 | -8 | 605 | -740 | 5 | 10233 | -2953 |
| Net Cash Flow | — | 103 | -92 | 156 | 22 | 77 | 22 | -12 |
| Free Cash Flow | — | 853 | 826 | -1423 | 987 | 1771 | 1895 | 2387 |
| CFO/OP | — | 97 | 96 | 71 | 112 | 103 | 98 | 102 |

### Ratios

| Item | Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 22 | 33 | 19 | 18 | 24 | 30 | 46 | 44 |
| Inventory Days | 166 | 175 | 243 | 265 | 188 | 180 | 219 | 193 |
| Days Payable | 71 | 145 | 137 | 162 | 126 | 90 | 119 | 121 |
| Cash Conversion Cycle | 117 | 63 | 125 | 121 | 86 | 120 | 146 | 117 |
| Working Capital Days | 56 | 30 | 32 | 24 | 39 | 53 | -28 | -40 |
| ROCE % | — | — | 37 | 32 | 22 | 26 | 17 | 14 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 76.5% | 76.5% | 74.88% | 74.87% | 74.87% | 72.71% | 72.7% | 72.68% | 72.67% | 72.66% | 72.66% | 72.63% |
| FIIs | 4.18% | 6.74% | 9.87% | 11.58% | 12.37% | 13.34% | 12.92% | 13.07% | 12.84% | 11.34% | 10.24% | 9.45% |
| DIIs | 4.39% | 9.49% | 11.14% | 9.95% | 9.9% | 11.06% | 11.48% | 11.5% | 11.92% | 13.25% | 14.46% | 15.39% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 1.11% | 1.14% | 1.22% | 1.46% | 1.55% | 1.6% | 1.64% | 1.52% | 1.36% | 1.52% | 1.39% | 1.29% |
| Others | 13.82% | 6.13% | 2.89% | 2.15% | 1.31% | 1.3% | 1.26% | 1.23% | 1.21% | 1.23% | 1.25% | 1.24% |
| No. of Shareholders | 134731 | 127449 | 135116 | 153450 | 163854 | 172431 | 180597 | 179549 | 170347 | 177539 | 177606 | 166715 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 1 / 6 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 2327.43 | Sell |
| EMA (10) | 2313.49 | Sell |
| SMA (20) | 2356.59 | Sell |
| EMA (20) | 2351.46 | Sell |
| SMA (50) | 2445.64 | Sell |
| EMA (50) | 2397.62 | Sell |
| SMA (100) | 2423.48 | Sell |
| EMA (100) | 2384.63 | Sell |
| SMA (200) | 2280.42 | Sell |
| EMA (200) | 2357.19 | Sell |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 37.57 | Neutral |
| MACD (12,26,9) | -45.18 | Sell |
| Stochastic (14,3,3) | 13.03 | Buy |
| ADX (14) | 23.64 | Neutral |
| Williams %R (14) | -71.27 | Neutral |
| ATR (14) | 51.25 | Neutral |
| ROC (12) | -4.75 | Sell |
| Stoch RSI (14) | 40.25 | Neutral |
| UO (7,14,28) | 42.37 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 10 | 52.63% |
| Hold | 5 | 26.32% |
| Sell | 4 | 21.05% |

Based on 19 analyst ratings, observed at 2026-09-11T04:51:42.743599+00:00.

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 8 May - Mankind Pharma will host Q4FY26 and FY26 investor call on May 20, 2026 at 12:00 PM IST. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 8 May - Mankind Pharma will host Q4FY26 and FY26 investor call on May 20, 2026 at 12:00 PM IST.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/6ee9fac3-d580-44b4-ba82-1495b8a564ec.pdf) |
| 7h - CARE assigned AA+/A1+ ratings to Mankind Pharma's ₹1,000 crore bank facilities. | [Announcement under Regulation 30 (LODR)-Credit Rating 7h - CARE assigned AA+/A1+ ratings to Mankind Pharma's ₹1,000 crore bank facilities.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/f9451a15-c2e5-4d12-96e0-70c32458673b.pdf) |
| 7 May - Board meets May 19, 2026 to approve FY26 audited results and realign security cover after ₹1,250 crore NCD redemption. | [Board Meeting Intimation for Inter Alia, Consider And Approve The Standalone And Consolidated Audited Financial Results Of The Company For The Quarter And Financial Year Ended On March 31, 2026 And Realignment Of Security Cover Provided In Respect Of Existing Ncds. 7 May - Board meets May 19, 2026 to approve FY26 audited results and realign security cover after ₹1,250 crore NCD redemption.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/2d45d75e-80de-4f50-bb2e-9e8c67c1e007.pdf) |
| 6 May - Annual Secretarial Compliance Report for FY2026 shows no non-compliance. | [Compliances-Reg.24(A)-Annual Secretarial Compliance 6 May - Annual Secretarial Compliance Report for FY2026 shows no non-compliance.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/2fea66e3-932b-4188-8649-eaa9ad3179d2.pdf) |
| 6 Apr - Submitted Regulation 74(5) certificate for quarter ended March 31, 2026; no demat/remat requests received. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Apr - Submitted Regulation 74(5) certificate for quarter ended March 31, 2026; no demat/remat requests received.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b5888d73-5e62-4aa6-a2a1-0f6e7d8f5d64.pdf) |
| 27 Mar - Trading window closed from April 01, 2026 until 48 hours after audited FY2026 results. | [Closure of Trading Window 27 Mar - Trading window closed from April 01, 2026 until 48 hours after audited FY2026 results.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ef7816ff-3ca6-49ee-aa39-84eeb49315b6.pdf) |
| 27 Feb - Feb 27, 2026: Mankind Pharma (Scrip 543904) clarifies volume increase; no undisclosed material event, market-driven. | [Clarification Submitted By Mankind Pharma Limited 27 Feb - Feb 27, 2026: Mankind Pharma (Scrip 543904) clarifies volume increase; no undisclosed material event, market-driven.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/33fa5709-5c00-4f37-a301-eea81b8d550d.pdf) |
| 26 Feb - CGST (Appeals) dropped INR 1,02,05,688 penalty for FY2017-18 to 2020-21 via Jan 28, 2026 order. | [Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015 26 Feb - CGST (Appeals) dropped INR 1,02,05,688 penalty for FY2017-18 to 2020-21 via Jan 28, 2026 order.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/56c33a97-48c8-45f6-99de-14c0e3b21694.pdf) |
| 24 Feb - ICRA reaffirmed Mankind Pharma ratings: ₹5,000cr NCDs AA+/Stable; ₹1,250cr fund limits AA+/A1+ on Feb 24, 2026. | [Announcement under Regulation 30 (LODR)-Credit Rating 24 Feb - ICRA reaffirmed Mankind Pharma ratings: ₹5,000cr NCDs AA+/Stable; ₹1,250cr fund limits AA+/A1+ on Feb 24, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d8d650ed-26c3-4f25-82f2-752dbc498b88.pdf) |
| 22 Apr - CARE assigned AA+/A1+ ratings to Mankind Pharma's ₹1,000 crore bank facilities. | [Announcement under Regulation 30 (LODR)-Credit Rating 22 Apr - CARE assigned AA+/A1+ ratings to Mankind Pharma's ₹1,000 crore bank facilities.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f9451a15-c2e5-4d12-96e0-70c32458673b.pdf) |

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-07 | [Update On Voluntary Liquidation Of WOS](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c592e0dd-e9d9-41aa-b40f-2dbb234c9846.pdf) |
| 2026-09-01 | [Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4c19f6b0-5084-4ac7-a3e4-76309909a456.pdf) |
| 2026-08-31 | [Update On Disinvestment](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9895ba81-e37f-4f95-ae10-75b51a01f19c.pdf) |
| 2026-08-30 | [Announcement under Regulation 30 (LODR)-Change in Management](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ec05fa37-f096-4dc1-b589-287e8149507b.pdf) |
| 2026-08-26 | [Board Meeting Outcome for Dated August 26 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d7b10f53-4dfe-49b2-83f1-d59eb3f49bbf.pdf) |
| 2026-08-26 | [Announcement under Regulation 30 (LODR)-Restructuring](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bb1e8a0a-d435-48a4-ac2e-74a395c6a105.pdf) |
| 2026-08-22 | [Intimation Regarding ESG Rating](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=86d78bcc-b941-4c0d-a35b-16be67ed8559.pdf) |
| 2026-08-20 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c2ae0831-36f6-4c43-8649-d41a8e22bcb9.pdf) |
| 2026-08-19 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c9b7b59-6245-4388-bc73-f29a6dcd4264.pdf) |
| 2026-08-18 | [Shareholder Meeting / Postal Ballot-Notice of Postal Ballot](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=efba1b50-1b04-4e00-a9f7-a430f9a2ada2.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-04 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=852ce86d-2a9a-4f1a-92c0-6977232784b6.pdf) |
| 2026-05-26 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ec60d351-ac60-4e7f-a77d-d4f035fe2703.pdf) |
| 2026-02-09 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=49858517-2821-4378-ab5b-bee857346a00.pdf) |
| 2025-11-11 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=09896907-dd89-468c-869d-25ae30374415.pdf) |
| 2025-08-06 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1c81dfdb-7723-4f42-a476-4753e4c7086b.pdf) |
| 2025-05-27 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b6d2d808-2fb6-4350-a73a-0df90d043dfa.pdf) |
| 2025-01-30 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=09cab4ef-bf88-40b1-be1e-cabdff929690.pdf) |
| 2024-11-11 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1fde1a79-c646-4353-b99b-69b0f12d9383.pdf) |
| 2024-08-06 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8d30e4d4-4e89-464c-bc32-91c670ef6391.pdf) |
| 2024-05-22 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d7a58344-29d8-4a71-baac-2e6db4d892a0.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-07-30 | [Un-Audited Financial Results Of The Company For The Quarter Ended On June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0a692344-6cbd-4f30-8cd1-19f11ecdfd23.pdf) |
| 2026-05-19 | [Financial Results For The Quarter And Financial Year Ended March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0cba202a-6ba8-4c13-a103-d47c07ca6098.pdf) |
| 2026-02-03 | [Financial Result For The Quarter And Nine Months Ended December 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=86b2b3ea-b33a-4bb0-9c64-b6298be2e468.pdf) |
| 2025-11-06 | [Financial Results For The Quarter And Half Year Ended 30Th September 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=740ea2bd-a613-4c62-b450-70ab75a552ed.pdf) |
| 2025-07-31 | [Un-Audited Financial Results For The Quarter Ended On June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2571e45e-4fa5-4ba5-8739-771a36c4ba7e.pdf) |
| 2025-05-21 | [Outcome Of Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5caf3035-d446-4f0b-9125-65393dca8fd5.pdf) |
| 2025-05-21 | [Outcome Of Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bf4d04fa-6dcd-4aa0-aab0-8add14647615.pdf) |
| 2024-11-05 | [Outcome Of Board Meeting Held Today I.E. November 5, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a35920d7-fea8-49a2-abe8-1d28afb26b80.pdf) |
| 2024-07-31 | [Outcome Of Board Meeting Held Today I.E. July 31, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=416167a9-edcf-4b2f-a6a5-39f8728d1708.pdf) |
| 2024-05-15 | [Regulation 30 And 33 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations').](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1d053d67-d33e-4e84-b6fa-60c29bb40f08.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-07-30 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f52efb65-7205-4441-8091-ac2e8c35dbe9.pdf) |
| 2026-05-19 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2d685134-1920-4e18-8f60-6d476c81457a.pdf) |
| 2026-02-03 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fa7f58c8-bb30-43c8-8184-df124142ee0b.pdf) |
| 2025-11-06 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7951849a-2f16-43f2-a94b-a1740f7d2ca1.pdf) |
| 2025-07-31 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9390a370-5720-4b96-8d2c-d1065a2ab458.pdf) |
| 2025-05-21 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6e768a11-e3f8-46fe-be52-d95b8ea90c41.pdf) |
| 2025-01-23 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8f508c34-1b16-40d2-b8e9-55cea708bdcf.pdf) |
| 2024-11-05 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bf840817-d664-47d4-858e-990b6fa71162.pdf) |
| 2024-09-02 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=87dce799-cad1-4805-8128-4d819376836c.pdf) |
| 2024-08-20 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ed70faa4-fc89-4b4a-a787-b72ae2e67a98.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-07-30 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c16c6989-c1f9-436d-b506-13c292d2de49.pdf) |
| 2026-05-20 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=18197725-cc6c-4d34-9c5b-66bb3637cb68.pdf) |
| 2026-02-03 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4eaabab0-76f0-465a-b532-c0cf52275450.pdf) |
| 2025-11-06 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0c33b4f6-3848-4e7e-8dc8-dcca5865bb30.pdf) |
| 2025-08-01 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=71c3a3ab-2448-4ed0-935e-1b9701933035.pdf) |
| 2025-05-21 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=16d5125f-cd4f-45b9-bb3a-65674a6c0eaf.pdf) |
| 2024-11-05 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=223ff998-8c61-443b-9f60-c34f38769011.pdf) |
| 2024-07-31 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ff718367-b61a-4cb7-9ace-d0914d6b48ff.pdf) |
| 2024-07-27 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8c181d00-75e8-4295-9156-0ba481f74f91.pdf) |
| 2024-05-16 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4bcb9ac8-2211-4578-ad64-c0cf0fb796e4.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Sep 2024 | [Concall - Sep 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/87dce799-cad1-4805-8128-4d819376836c.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/09896907-dd89-468c-869d-25ae30374415.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1fde1a79-c646-4353-b99b-69b0f12d9383.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/dbb2a66f-ad87-4ce6-9a07-70740af925ec.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ec60d351-ac60-4e7f-a77d-d4f035fe2703.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/ec60d351-ac60-4e7f-a77d-d4f035fe2703.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2d685134-1920-4e18-8f60-6d476c81457a.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/2d685134-1920-4e18-8f60-6d476c81457a.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b6d2d808-2fb6-4350-a73a-0df90d043dfa.pdf) |
| May 2024 | [Concall - May 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d7a58344-29d8-4a71-baac-2e6db4d892a0.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8d06aceb-5f6d-4492-bac3-ad6b6d063172.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f4249a79-2986-44b0-b7d4-a24ec3409ba9.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b6f4cbc2-fac4-4ed6-9738-115aa45b2eb7.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0b98b421-ddb7-4c51-93e8-c2e6c35e6db2.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:59:13.257Z.